Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Tildrakizumab> ?p ?o }
Showing triples 1 to 54 of
54
with 100 triples per page.
- Tildrakizumab abstract "Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune system and autoimmune disease. Originally developed by Schering-Plough, this drug is now part of Merck's clinical program, following that company's acquisition of Schering-Plough.Sun Pharmaceutical acquired worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Upon product approval, Sun Pharmaceutical will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. As of March 2014, the drug was in phase III clinical trials for plaque psoriasis. The two trials will enroll a total of nearly 2000 patients, and preliminary results are expected in June, 2015.".
- Tildrakizumab atcPrefix "none".
- Tildrakizumab casNumber "1326244-10-3".
- Tildrakizumab wikiPageID "36964648".
- Tildrakizumab wikiPageLength "2696".
- Tildrakizumab wikiPageOutDegree "15".
- Tildrakizumab wikiPageRevisionID "707386954".
- Tildrakizumab wikiPageWikiLink Autoimmune_disease.
- Tildrakizumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Tildrakizumab wikiPageWikiLink Cytokine.
- Tildrakizumab wikiPageWikiLink Guselkumab.
- Tildrakizumab wikiPageWikiLink Immune_system.
- Tildrakizumab wikiPageWikiLink Interleukin_23.
- Tildrakizumab wikiPageWikiLink Interleukin_23_subunit_alpha.
- Tildrakizumab wikiPageWikiLink Merck_&_Co..
- Tildrakizumab wikiPageWikiLink Monoclonal_antibody.
- Tildrakizumab wikiPageWikiLink Phases_of_clinical_research.
- Tildrakizumab wikiPageWikiLink Psoriasis.
- Tildrakizumab wikiPageWikiLink Schering-Plough.
- Tildrakizumab wikiPageWikiLink Sun_Pharmaceutical.
- Tildrakizumab wikiPageWikiLink Ustekinumab.
- Tildrakizumab wikiPageWikiLinkText "Tildrakizumab".
- Tildrakizumab atcPrefix "none".
- Tildrakizumab c "6426".
- Tildrakizumab casNumber "1326244".
- Tildrakizumab chemspiderid "none".
- Tildrakizumab h "9918".
- Tildrakizumab molecularWeight "144.4".
- Tildrakizumab n "1698".
- Tildrakizumab o "2000".
- Tildrakizumab s "46".
- Tildrakizumab source "zu/o".
- Tildrakizumab target Interleukin_23.
- Tildrakizumab type "mab".
- Tildrakizumab wikiPageUsesTemplate Template:Drugbox.
- Tildrakizumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Tildrakizumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Tildrakizumab subject Category:Monoclonal_antibodies.
- Tildrakizumab hypernym Antibody.
- Tildrakizumab type ChemicalSubstance.
- Tildrakizumab type Drug.
- Tildrakizumab type Antibody.
- Tildrakizumab type Chemical.
- Tildrakizumab type Drug.
- Tildrakizumab type ChemicalObject.
- Tildrakizumab type Thing.
- Tildrakizumab type Q8386.
- Tildrakizumab comment "Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune system and autoimmune disease.".
- Tildrakizumab label "Tildrakizumab".
- Tildrakizumab sameAs Q15708331.
- Tildrakizumab sameAs m.0n4btz7.
- Tildrakizumab sameAs Q15708331.
- Tildrakizumab wasDerivedFrom Tildrakizumab?oldid=707386954.
- Tildrakizumab isPrimaryTopicOf Tildrakizumab.